proline rich and Gla domain 3Genealiases: PRGP3 · TMG3
Q-omics provides the consensus-scored PRRG3 profile across patient tissues and cancer cell-line models. PRRG3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRRG3 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, PRRG3 RNA expression shows 15,495 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where PRRG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRRG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRRG3 survival associations across molecular data types. PRRG3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (10) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRRG3 RNA expression–survival associations across cancer types. High PRRG3 expression shows unfavorable associations in KIRP, SKCM and OV, but favorable associations in KIRC, HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRRG3 RNA expression.
This table summarizes PRRG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PRRG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRRG3 shows lower tumor expression in BLCA, LUAD, COAD, KIRP and BRCA and higher tumor expression in LIHC. The BLCA box plot shows higher PRRG3 RNA expression in normal versus tumor tissue (log2 FC = −1.682, t-test p < 0.001).
This table shows molecular features associated with PRRG3 in patient tissues and cancer cell lines. In patient samples, PRRG3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRRG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
